Anuradha Jayaram

Plasma <i>AR</i> and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca et al. · Science Translational Medicine · 2015 · 441 citations · Full text

Medicine, Oncology, Pharmacology +14

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber et al. · JAMA Oncology · 2018 · 238 citations · Full text

Medicine, Oncology, Pharmacology +17

Genome-wide plasma DNA methylation features of metastatic prostate cancer

Anjui Wu, Paolo Cremaschi, Daniel Wetterskog et al. · Journal of Clinical Investigation · 2020 · 105 citations · Full text

Medicine, Genetics, Oncology +17

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

Pasquale Rescigno, David Lorente, Diletta Bianchini et al. · European Urology · 2016 · 70 citations · Full text

Medicine, Oncology, Urology +16